Experimental drug for cholesterol and fatty liver fails to advance

NCT ID NCT06007651

Terminated Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested a new drug called LY3885125 in people with high cholesterol (dyslipidemia) and non-alcoholic fatty liver disease (NAFLD). The main goal was to check safety and how the body processes the drug. The study was terminated, meaning it stopped early, so its potential remains unclear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3885125
What this could lead to: If successful, this could point toward a new treatment option for managing high cholesterol and fatty liver disease.
What could go wrong: This was a very early (Phase 1) trial focused on safety, not effectiveness. The study was terminated, so results may not be available or may not support further development.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias hyperlipidemia inherited lipid metabolism disorder metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDEMIAS NON-ALCOHOLIC FATTY LIVER DISEASE

Contacts and locations

Locations

Worldwide Clinical Trials, Inc.

San Antonio, Texas, 78217, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.